elranatamab
pfizer
['magnetismm-3', 'mmsm', 'elranatamab']
#ash22 #mmsm elranatamab-magnetismm-3 "peripheral neuropathy was reported in 17.1% (grade 3/4, 0.8%) of pts; most common events ( 2% of pts) were peripheral sensory neuropathy (4.9% [no grade 3/4]), paresthesia (4.1% [no grade 3/4]) and gait disturbance (2.4% [no grade 3/4])"
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities